Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.4)
Index Copernicus  – 161.11; MEiN – 140 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2018, vol. 27, nr 7, July, p. 867–872

doi: 10.17219/acem/68945

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Rise in antifibrotic and decrease in profibrotic microRNA protect the heart against fibrosis during pregnancy: A preliminary study

Ewa Szczerba1,2,A,B,C,D,F, Agnieszka Zajkowska3,A,B,C,D,F, Anna Bochowicz1,A,B,E,F, Katarzyna Pankiewicz4,B,C,D,F, Grzegorz Szewczyk4,5,B,C,E,F, Katarzyna Markiewicz6,B,C,E,F, Grzegorz Opolski2,A,C,E,F, Tomasz Maciejewski4,A,B,C,E,F, Maciej Małecki3,A,C,E,F, Anna Fijałkowska1,A,-F

1 Department of Cardiology, Institute of Mother and Child, Warszawa, Poland

2 1st Department of Cardiology, Medical University of Warsaw, Poland

3 Department of Applied Pharmacy and Bioengineering, Medical University of Warsaw, Poland

4 Department of Obstetrics and Gynecology, Institute of Mother and Child, Warszawa, Poland

5 Department of General and Experimental Pathology, Medical University of Warsaw, Poland

6 Department of Clinical Immunology, Institute of Mother and Child, Warszawa, Poland


Background. Physiological pregnancy is associated with volume overload. Unlike cardiac pathologies linked with volume overload, such as mitral or aortic regurgitation, pregnancy is thought to be unrelated to fibrosis of the heart. However, changes in the cardiac extracellular matrix during pregnancy remain poorly understood.
Objectives. The aim of the study was to examine the expression of 11 microRNAs associated with cardiac fibrosis (miR-21, miR-26a, miR-26b-5p, miR-29b-3p, miR-29c-3p, miR-101a, miR-146a, miR-208a, miR-223 and miR-328) during pregnancy and to compare them with a healthy control group.
Material and Methods. Six women in singleton pregnancy (30–36 weeks) and 6 non-pregnant women as a control group were included in the study. Each woman underwent an echocardiographic examination, and had blood pressure on both arms measured and a blood sample taken. MicroRNAs expression was analyzed using Custom TaqMan® Array MicroRNA Cards (Applied Biosystems, Foster City, USA).
Results. Median age of the pregnant women was 34 years (range 25–39 years) and of the control group 32 years (range 29-43 years). Median week of pregnancy was 34 years (range 31–36 years). Most of the examined microRNAs had a lower expression in the pregnancy group (fold change 1.0).
Conclusion. In the 3rd trimester of physiological pregnancy, there is a 244% increase in expression of miR-101a and a decrease by 73% in expression of miR-328. Both of these changes can protect against fibrosis during volume overload occurring in physiological pregnancy.

Key words

pregnancy, microRNA, cardiac remodeling, cardiac fibrosis, volume overload

References (25)

  1. Goldsmith EC, Bradshaw AD, Zile MR, Spinale F. Myocardial fibroblast-matrix interactions and potential therapeutic targets. J Mol Cell Cardiol. 2014;70:92–99.
  2. Bowers SLK, Banerjee I, Baudino TA. The extracellular matrix: At the center of it all. J Mol Cell Cardiol. 2010;48:474–482.
  3. Hutchinson KR, Stewart JA, Lucchesi PA. Extracellular matrix remodeling during the progression of volume overload-induced heart failure. J Mol Cell Cardiol. 2010;48:564–569.
  4. Chung E, Leinwand LA. Pregnancy as a cardiac stress model. Cardiovasc Res. 2014;101:561–570.
  5. Sanghavi M, Rutherford JD. Cardiovascular physiology of pregnancy. Circulation. 2014;130:1003–1008.
  6. Zhao X, Wang K, Liao Y, et al. MicroRNA-101a inhibits cardiac fibrosis induced by hypoxia via targeting TGFβRI on cardiac fibroblasts. Cell Physiol Biochem. 2015;35:213–226.
  7. He F, Lv P, Zhao X, et al. Predictive value of circulating miR-328 and miR-134 for acute myocardial infarction. Mol Cell Biochem. 2014;394:137–144.
  8. Watson CJ, Gupta SK, O’Connell E, et al. MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure. Eur J Heart Fail. 2015;17:405–415.
  9. Yang SF, Lee WJ, Tan P, et al. Upregulation of miR-328 and inhibition of CREB-DNA-binding activity are critical for resveratrol-mediated suppression of matrix metalloproteinase-2 and subsequent metastatic ability in human osteosarcomas. Oncotarget. 2015;6:2736–2753.
  10. Liu X, Dong Y, Chen S, et al. Circulating microRNA-146a and microRNA-21 predict left ventricular remodeling after ST-elevation myocardial infarction. Cardiology. 2015;132:233–241.
  11. Lorenzen JM, Schauerte C, Hübner A, et al. Osteopontin is indispensable for AP1-mediated angiotensin II-related miR-21 transcription during cardiac fibrosis. Eur Heart J. 2015;36:2184–2196.
  12. Ning Q, Jiang X. Angiotensin II upregulated the expression of microRNA-224 but not microRNA-21 in adult rat cardiac fibroblasts. Biomed Rep. 2013;5:776–780.
  13. Wei C, Kim IK, Kumar S, et al. NF-κB mediated miR-26a regulation in cardiac fibrosis. J Cell Physiol. 2013;228:1433–1442.
  14. Zhang ZH, Li J, Liu BR, et al. MicroRNA-26 was decreased in rat cardiac hypertrophy model and may be a promising therapeutic target. J Cardiovasc Pharmacol. 2013;62:312–319.
  15. He Y, Huang C, Lin X, Li J. MicroRNA-29 family, a crucial therapeutic target for fibrosis diseases. Biochimie. 2013;95:1355–1359.
  16. van Rooij E, Sutherland LB, Thatcher JE, et al. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A. 2008;105:13027–13032.
  17. Abonnenc M, Nabeebaccus AA, Mayr U, et al. Extracellular matrix secretion by cardiac fibroblasts: Role of microRNA-29b and microRNA-30c. Circ Res. 2013;113:1138–1147.
  18. Zhang G, Shi H, Wang L, et al. MicroRNA and transcription factor mediated regulatory network analysis reveals critical regulators and regulatory modules in myocardial infarction. PLoS One. 2015;10(8):e0135339.
  19. Tanbe AF, Khali RA. Circulating and vascular bioactive factors during hypertension in pregnancy. Curr Bioact Compd. 2010;6:60–75.
  20. Mizutani S, Tomoda Y. Effects of placental proteases on maternal and fetal blood pressure in normal pregnancy and preeclampsia. Am J Hypertens. 1996;9:591–597.
  21. Furuhashi N, Tsujiei M, Kimura H, Yajima A, Nahae H, Kimur C. Maternal and fetal atrial natriuretic peptide levels, maternal plasma renin activity, angiotensin II, prostacyclin and thromboxane A2 levels in normal and preeclamptic pregnancies. Tohoku J Exp Med. 1991;165:79–86.
  22. Mizutani S, Tamodo Y. Effects of placental proteases on maternal and fetal blood pressure in normal pregnancy and preeclampsia. Am J Hypertens. 1996;9:591–597.
  23. Cirera S, Moesgaard SG, Zois NE, et al. Plasma proANP and SDMA and microRNAs are associated with chronic mitral regurgitation in a pig model. Endocr Connect. 2013;2:161–171.
  24. Li Q, Freeman LM, Rush JE, Laflamme DP. Expression profiling of circulating microRNAs in canine myxomatous mitral valve disease. Int J Mol Sci. 2015;16:14098–14108.
  25. Nigam V, Sievers HH, Jensen BC, et al. Altered microRNAs in bicuspid aortic valve: A comparison between stenotic and insufficient valves. J Heart Valve Dis. 2010;19:459–465.